Google
English
French
German
Italian
Japanese
Portuguese
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
FDA Approves Subcutaneous Daratumumab Plus VCd for Newly Diagnosed Light-Chain Amyloidosis
The FDA has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro), a subcutaneous formulation of daratumumab, for use in combination with bortezomib, cyclophosphamide, and dexamethasone (D-VCd; VCd) in the treatment of patients with newly diagnosed light-chain amyloidosis.
Continued approval for this indication could be dependent upon verification and description of clinical benefit in a confirmatory trial, according to Genmab.
Notably, the subcutaneous formulation is not indicated and is not recommended for the treatment of patients with light-chain myloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials.
The regulatory decision was based on data from the phase 3 ANDROMEDA (AMY3001), which showed that the regimen resulted in an improved hematologic complete response (CR) rate versus VCd alone in this patient population.
Source: www.onclive.com
myBinderRelated Content
-
Vaishali Sanchorawala, MDVaishali Sanchorawala is the Director of...
-
Treatment Considerations for Patients Exceeding 10% Plasma Cells – ASG Webinar 11/13https://www.youtube.com/watch?v=4gUXPbOk...
-
Heather J. Landau, MDHeather J. Landau is a board-certified o...
-
Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and TherapyImmunoglobulin amyloid light-chain (AL) ...
-
Alexion Pharmaceuticals Partners With Caelum Biosciences to Tackle Light Chain AmyloidosisAlexion Pharmaceuticals (ALXN) has been ...
-
Future AL Amyloidosis Treatmenthttps://www.youtube.com/watch?v=K25lurau...
-
AL Amyloidosis: From Molecular Mechanisms to Targeted TherapiesSystemic amyloidosis is caused by misfol...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
